Chiltern Announces New Legal Entity in Israel
Chiltern International Limited (Chiltern), a global clinical contract research organization (CRO), announced that the company has established a new legal entity in Israel.
“Chiltern has experienced a healthy number of requests from our clients in this region and forming a legal entity is a natural progression to our work there,” commented Armand Czaplinski, Chiltern’s Executive Director, Global Country Management, who will be leading the effort in Israel. “Israel is an attractive location to conduct clinical trials as it has many key opinion leaders (KOL) in clinical research and outstanding quality of research. Israel has some of the most skilled and educated work forces with the highest number of doctors, scientists, and engineers per capita than any other country. Another key advantage is that the majority of Israel’s population belongs to the same health maintenance organization and this facilitates quick start for clinical trials and reduces the overall project timelines.”
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
